LBLaetitia Bossevot

Laetitia Bossevot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laetitia Bossevot has a total of 90 co-authors. Here are the top co-authors by number of shared publications:

  • Nathalie Dereuddre-Bosquet

    Université Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral Auto-immune, Hematological and Bacterial diseases (IMVA-HB/ IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France

    9 shared publications
  • Roger Le Grand

    Paris-Saclay University, INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT/UMRS1184)

    9 shared publications
  • Francis Relouzat

    Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France

    7 shared publications
  • Mariangela Cavarelli

    Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France

    6 shared publications
  • Quentin Pascal

    Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Viral Diseases (IMVA-HB/IDMIT), Paris, France

    4 shared publications
  • Wesley Gros

    Université Paris-Saclay, Inserm, CEA, Immune diseases, microbiology and innovative therapies (IDMIT/UMRS1184), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France

    3 shared publications

Latest Publications

  • Open Access

    OVX033 nucleocapsid vaccine induces cross-reactive T cells and boosts memory in SARS-CoV-2-primed non-human primates

    by Romain Marlin, Charlotte Primard, Anne-Sophie Gallouët, Alice Indalecio, Nathalie Dereuddre-Bosquet, Delphine Nourissat, Mariangela Cavarelli, Séverine Valsesia, Mélanie Robin, Wesley Gros, et al.

    SARS-CoV-2 Spike protein evolution compromises sustained efficacy of existing vaccines based on neutralizing antibodies. Here we show that OVX033, a nucleocapsid (NCAP)-based vaccine candidate engineered with the self-assembling oligoDOM™ domain, induces robust cellular immunity in two preclinical models. In hamsters, OVX033 elicits robust systemic and pulmonary IFN-γ T-cell responses, cross-reactive across variants, whereas non-assembled NCAP fails to induce T-cell immunity. In non-human primates, adjuvanted OVX033 triggers NCAP-specific antibodies and polyfunctional CD4 + T cells with Th1/Th17 profiles at both systemic and mucosal sites. A single non-adjuvanted dose of OVX033 recalls potent humoral and Th1 T-cell response in SARS-CoV-2 convalescent macaques. These findings show that OVX033 significantly enhances T-cell immunity compared to the native NCAP and that prior infection reduces the need for repeated dosing and adjuvant use. By targeting a conserved viral antigen, OVX033 supports further clinical evaluation as a complementary T-cell-based vaccine strategy against sarbecoviruses.

  • Open Access

    Maintenance of intestinal CX3CR1+ macrophage homeostasis defines post-treatment control in SIV-infected macaques

    by Stéphane Hua, Keltouma Benmeziane, Delphine Desjardins, Nastasia Dimant, Marco Leonec, Laetitia Bossevot, Julien Lemaitre, Adeline Mélard, Francis Relouzat, VérOnique Avettand-Fenoël, et al.

    Achieving durable viral remission without antiretroviral therapy (ART) remains a central challenge in HIV-1 cure research. Using a pathogenic SIV model in male cynomolgus macaques, we investigated mucosal and systemic immune features associated with post-treatment control (PTC). Chronic SIV infection disrupts intestinal macrophage homeostasis, skewing the compartment toward a CX3CR1 low inflammatory phenotype marked by increased expression of costimulatory and homing markers. This polarization is associated with mucosal CD4 + T cell depletion, elevated neutrophil activation, and systemic cytokine induction. Non-controllers exhibit a similar inflammatory profile. In contrast, PTCs maintain CX3CR1 high macrophages, preserve regulatory CD4 + T cells, and exhibit attenuated mucosal and systemic immune activation, resembling uninfected animals. CX3CR1 high macrophage abundance inversely correlates with viral burden, T cell activation, and pro-inflammatory cytokines, suggesting a potential role in post-treatment control. These findings identify CX3CR1-expressing intestinal macrophages as a potential biomarker of mucosal immune regulation and highlight their relevance as targets in HIV cure strategies.


  • Open Access

    Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model

    by Cécile Herate, Audrey Ferrier-Rembert, Francis Relouzat, Anne-Sophie Gallouët, Quentin Pascal, Hélène Letscher, Mariangela Cavarelli, Nathalie Dereuddre-Bosquet, Wesley Gros, Benoit Delache, et al.

    The monkeypox virus (MPXV) outbreak of 2022 caused a human disease with unusual epidemiological and clinical features, notably an increase in human-to-human transmission through sexual contact, predominantly among men who have sex with men (MSM). This evolution underscores the need to reassess prevention and control strategies in the context of a sexually transmitted disease. Here, we show that rectal challenge of male cynomolgus macaques with a 2022 clade IIb MPXV isolate mimics sexual transmission, leading to rectal infection, with systemic and male genital tract dissemination and seminal fluid shedding. Vaccination with modified-vaccinia Ankara (MVA) protected the macaques from subsequent rectal MPXV challenge. However, MVA failed to prevent the disease when administered four days post-exposure to MPXV. These findings have a critical impact on outbreak management and highlight the importance of reevaluating MVA post-exposure prophylaxis protocols.


  • Open Access

    Whole-body visualization of SARS-CoV-2 biodistribution in vivo by immunoPET imaging in non-human primates

    by Alexandra Detrille, Steve Huvelle, Marit J. van Gils, Tatiana Geara, Quentin Pascal, Jonne Snitselaar, Laetitia Bossevot, Mariangela Cavarelli, Nathalie Dereuddre-Bosquet, Francis Relouzat, et al.

    The COVID-19 pandemic has caused at least 780 million cases globally. While available treatments and vaccines have reduced the mortality rate, spread and evolution of the virus are ongoing processes. Despite extensive research, the long-term impact of SARS-CoV-2 infection is still poorly understood and requires further investigation. Routine analysis provides limited access to the tissues of patients, necessitating alternative approaches to investigate viral dissemination in the organism. We address this issue by implementing a whole-body in vivo imaging strategy to longitudinally assess the biodistribution of SARS-CoV-2. We demonstrate in a COVID-19 non-human primate model that a single injection of radiolabeled [89Zr]COVA1-27-DFO human monoclonal antibody targeting a preserved epitope of the SARS-CoV-2 spike protein allows longitudinal tracking of the virus by positron emission tomography with computed tomography (PET/CT). Convalescent animals exhibit a persistent [89Zr]COVA1-27-DFO PET signal in the lungs, as well as in the brain, three months following infection. This imaging approach also allows viral detection in various organs, including the airways and kidneys, of exposed animals during the acute infection phase. Overall, the technology we developed offers a comprehensive assessment of SARS-CoV-2 distribution in vivo and provides a promising approach for the non-invasive study of long-COVID pathophysiology.


  • Open Access

    Difference in the efficacy of the modified-vaccinia Ankara vaccine as pre-exposure and post-exposure prophylaxis against sexual transmission of monkeypox virus clade IIb in non-human primates

    by Cécile Herate, Audrey Ferrier-Rembert, Francis Relouzat, Anne-Sophie Gallouet, Quentin Pascal, Hélène Letscher, Mariangela Cavarelli, Nathalie Bosquet, Wesley Gros, Benoit Delache, et al.

    The monkeypox virus (MPXV) outbreak of 2022 caused a human disease with unusual epidemiological and clinical features, notably an increase in human-to-human transmission through sexual contact, predominantly among men who have sex with men (MSM). This evolution underscores the need to reassess prevention and control strategies in the context of a sexually transmitted disease. Here, we show that rectal challenge of cynomolgus macaques with a 2022 clade IIb MPXV isolate mimics sexual transmission, leading to rectal infection, with systemic and male genital tract dissemination and seminal fluid shedding. Vaccination with modified-vaccinia Ankara (MVA) protected the macaques from subsequent rectal MPXV challenge. However, MVA failed to prevent the disease when administered four days post-exposure to MPXV. These findings have a critical impact on outbreak management and highlight the importance of reevaluating MVA post-exposure prophylaxis protocols.

  • Open Access

    Boost and Increased Antibody Breadth Following a Second Dose of PARVAX for SARS-CoV-2 in Mice and Nonhuman Primates

    by Urja Bhatt, Cecile Herate, Reynette Estelien, Francis Relouzat, Nathalie Dereuddre-Bosquet, Dawid Maciorowski, Cheikh Diop, Emma Couto, Jillian Staiti, Mariangela Cavarelli, et al.

    PARVAX is a genetic vaccine platform based on an adeno-associated vector that has demonstrated to elicit potent, durable, and protective immunity in nonhuman primates (NHPs) after a single dose. Here, we assessed vaccine immunogenicity following a PARVAX prime-boost regimen against SARS-CoV-2. In mice, a low-dose prime followed by a higher-dose boost elicited potent neutralizing antibody responses and distinct cross-reactivity profiles, depending on the antigen used in the booster vaccine. However, the potent neutralizing anti-vector antibody responses developed in mice limited the dose that could be administered as a prime. We further explored the re-administration efficacy in NHPs primed with a SARS-CoV-2 Delta vaccine and boosted with an Omicron BA.1 vaccine at week 15, after the primary response peak antibody levels were reached. The boost elicited an increase in antibodies against several Omicron variants, but no increase was detected in the antibody titers for other variants. The anti-vector responses were low and showed some increased subsequent boosts but generally declined over time. The potent prime vaccination limited the detection of the boosting effect, and therefore, the effect of anti-vector immunity was not fully elucidated. These data show that PARVAX can be effectively re-administered and induce a novel antigenic response.

  • Open Access

    Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging

    by Katia Lemdani, Romain Marlin, Céline Mayet, Vladimir Perkov, Quentin Pascal, Manon Ripoll, Francis Relouzat, Nina Dhooge, Laetitia Bossevot, Nathalie Dereuddre-Bosquet, et al.

    The characterization of vaccine distribution to relevant tissues after in vivo administration is critical to understanding their mechanisms of action. Vaccines based on mRNA lipid nanoparticles (LNPs) are now being widely considered against infectious diseases and cancer. Here, we used in vivo imaging approaches to compare the trafficking of two LNP formulations encapsulating mRNA following intramuscular administration: DLin-MC3-DMA (MC3) and the recently developed DOG-IM4. The mRNA formulated in DOG-IM4 LNPs persisted at the injection site, whereas mRNA formulated in MC3 LNPs rapidly migrated to the draining lymph nodes. Furthermore, MC3 LNPs induced the fastest increase in blood neutrophil counts after injection and greater inflammation, as shown by IL-1RA, IL-15, CCL-1, and IL-6 concentrations in nonhuman primate sera. These observations highlight the influence of the nature of the LNP on mRNA vaccine distribution and early immune responses.


  • Open Access

    Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure

    by Karunasinee Suphaphiphat, Delphine Desjardins, Valérie Lorin, Nastasia Dimant, Kawthar Bouchemal, Laetitia Bossevot, Maxence Galpin-Lebreau, Nathalie Dereuddre-Bosquet, Hugo Mouquet, Roger Le Grand, et al.

    Passive immunization using broadly neutralizing antibodies (bNAbs) is investigated in clinical settings to inhibit HIV-1 acquisition due to the lack of a preventive vaccine. However, bNAbs efficacy against highly infectious cell-associated virus transmission has been overlooked. HIV-1 transmission mediated by infected cells present in body fluids likely dominates infection and aids the virus in evading antibody-based immunity. Here, we show that the anti-N-glycans/V3 loop HIV-1 bNAb 10-1074 formulated for topical vaginal application in a microbicide gel provides significant protection against repeated cell-associated SHIV162P3 vaginal challenge in non-human primates. The treated group has a significantly lower infection rate than the control group, with 5 out of 6 animals fully protected from the acquisition of infection. The findings suggest that mucosal delivery of potent bnAbs may be a promising approach for preventing transmission mediated by infected cells and support the use of anti-HIV-antibody-based strategies as potential microbicides in human clinical trials.


  • Open Access

    Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera

    by Pierre Roques, Andrea Fritzer, Nathalie Dereuddre-Bosquet, Nina Wressnigg, Romana Hochreiter, Laetitia Bossevot, Quentin Pascal, Fabienne Guehenneux, Annegret Bitzer, Irena Corbic Ramljak, et al.

    Chikungunya virus (CHIKV) is a reemerging mosquito-borne alphavirus responsible for numerous outbreaks. Chikungunya can cause debilitating acute and chronic disease. Thus, the development of a safe and effective CHIKV vaccine is an urgent global health priority. This study evaluated the effectiveness of the live-attenuated CHIKV vaccine VLA1553 against WT CHIKV infection by using passive transfer of sera from vaccinated volunteers to nonhuman primates (NHP) subsequently exposed to WT CHIKV and established a serological surrogate of protection. We demonstrated that human VLA1553 sera transferred to NHPs conferred complete protection from CHIKV viremia and fever after challenge with homologous WT CHIKV. In addition, serum transfer protected animals from other CHIKV-associated clinical symptoms and from CHIKV persistence in tissue. Based on this passive transfer study, a 50% micro–plaque reduction neutralization test titer of ≥ 150 was determined as a surrogate of protection, which was supported by analysis of samples from a seroepidemiological study. In conclusion, considering the unfeasibility of an efficacy trial due to the unpredictability and explosive, rapidly moving nature of chikungunya outbreaks, the definition of a surrogate of protection for VLA1553 is an important step toward vaccine licensure to reduce the medical burden caused by chikungunya.